NeuroCME
EXPERT VIDEOCME

Navigating Advancing Science in Progressive MS

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN, FANA; Guy J. Buckle, MD, MPH; Stephen Krieger, MD, FAAN
Release Date: 7/25/2019Expiration Date: 7/24/2020
Credit Type: CMENumber of Credits: 1
Content Type: VideoProvider:
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system that represents the most common cause of nontraumatic neurological disability in young adults. Approximately 10% to 15% of patients with MS have primary progressive MS (PPMS), which, from onset, involves unremitting disease progression, without distinct relapses. Advances in the understanding of the pathogenesis of MS have resulted in the development of improved therapeutic approaches, including an emphasis on early treatment with disease-modifying therapies (DMTs), and the incorporation of magnetic resonance imaging into diagnostic and monitoring strategies. In 2017, ocrelizumab became the first therapy to receive US Food and Drug Administration approval for the treatment of PPMS. Ocrelizumab’s status as the first drug approved for PPMS heralds a radical shift in the treatment paradigm for this disease. Rather than just managing symptoms, physicians now can modify the progressive course of the disease in many patients. In this CME activity, experts will discuss the impact of early versus later treatment on the progression of MS, assess the role of nonconventional imaging techniques in the management of patients with MS, as well as discuss how to incorporate new clinical trial data into clinical practice regarding new and emerging DMTs for the treatment of patients with PPMS.